{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-300545","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.477254+00:00","generated_at":"2026-06-21T07:42:03.025103+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics reduces workforce by 40%, closes Boston site, extends cash runway to H2 2025","bullets":["Workforce reduction of ~40% to cut operating expenses; one-time charge of ~$1.0M expected in Q4 2022/Q1 2023.","Boston research site closed; operations consolidated to Rockville, MD; cash runway extended into H2 2025.","Robert Pierce terminated as Chief R&D Officer; moves to consulting role as Science Fellow effective Dec 7, 2022.","Edward van der Horst promoted to Chief Scientific Officer effective Dec 7, 2022; oversees SNS-101 development.","IND submission for lead antibody SNS-101 (anti-VISTA) anticipated by April 2023; discovery work on VSIG-4 and CD39 continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-300545","json":"https://secwatch.observer/filing/0001193125-22-300545.json","markdown":"https://secwatch.observer/filing/0001193125-22-300545.md","text":"https://secwatch.observer/filing/0001193125-22-300545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/0001193125-22-300545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/d431901d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:42:03.025103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39c7d21b18","claim":"Robert Pierce was terminated as Chief Research and Development Officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"On December 7, 2022, the Company notified Robert Pierce, who had been serving as the Company’s Chief Research and Development Officer, that his employment with the Company would terminate, effective December 7, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/0001193125-22-300545-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Research and Development Officer"}],"fact_type":"executive_change"},{"claim_id":"92eb4e50b6e336ee8745fbfd204f2ef0a6198f3e","claim":"Sensei Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.0 million affecting Company (approximately 40% of its workforce).","evidence_excerpt":"On December 5, 2022, the Board of Directors of Sensei Biotherapeutics, Inc. (the “Company”) approved a plan to reduce the Company’s current workforce by approximately 40% to decrease operating expenses. The Company expects the reduction in force to be substantially completed in the first quarter of 2023. As a result, the Company estimates that it will incur a one-time charge of approximately $1.0 million in connection with one-time employee termination costs, including severance and other benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/0001193125-22-300545-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.0 million"},{"label":"Affected area","value":"Company"},{"label":"Headcount","value":"approximately 40% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}